Hepatitis C Virus and Human Immunodeficiency Virus Coinfection in an Urban Population: Low Eligibility for Interferon Treatment

One hundred eighty human immunodeficiency virus (HIV)– and hepatitis C virus (HCV)–coinfected patients were prospectively evaluated for suitability for interferon and ribavirin therapy. Of the 149 patients with chronic HCV infection who completed the evaluation, 44 (30%) were eligible for treatment...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2003-01, Vol.36 (1), p.97-100
Main Authors: Fleming, Catherine A., Craven, Donald E., Thornton, David, Tumilty, Sheila, Nunes, David
Format: Article
Language:English
Subjects:
Adult
AIDS
Antiviral Agents - therapeutic use
Biological and medical sciences
Biopsies
Drug Therapy, Combination
Eligibility Determination
Female
Genotypes
Hepacivirus
Hepatitis C - complications
Hepatitis C - drug therapy
HIV
HIV Infections - complications
HIV Infections - drug therapy
HIV/AIDS
Human viral diseases
Humans
Infections
Infectious diseases
Interferons - therapeutic use
Liver
Liver diseases
Male
Medical sciences
Mental illness
Middle Aged
Prospective Studies
Ribavirin - therapeutic use
Urban Health
Urban Population
Viral diseases
Viral hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:One hundred eighty human immunodeficiency virus (HIV)– and hepatitis C virus (HCV)–coinfected patients were prospectively evaluated for suitability for interferon and ribavirin therapy. Of the 149 patients with chronic HCV infection who completed the evaluation, 44 (30%) were eligible for treatment and 105 (70%) were ineligible, with the main barriers being missed clinic visits, active psychiatric illness, active drug or alcohol use, decompensated liver disease, or medical illness.
ISSN:1058-4838
1537-6591
DOI:10.1086/344907